What are the shared DNA methylation age acceleration and histone modification patterns across Alzheimer disease, Parkinson disease, and Amyotrophic Lateral Sclerosis? Identify common epigenetic signatures that distinguish these neurodegenerative diseases from normal aging.
HDAC6 Inhibitor Therapy for Pan-Neurodegenerative Protein Homeostasis
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["HDAC6 Inhibition"]
B["Alpha-tubulin Acetylation Increase"]
C["Microtubule Stabilization"]
D["Autophagy Flux Restoration"]
E["Proteostasis Improvement"]
F["Pan-neurodegenerative Protein Clearance"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Median TPM across 13 brain regions for HDAC6 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
10 citations10 with PMIDValidation: 0%5 supporting / 5 opposing
✓For(5)
No supporting evidence
No opposing evidence
(5)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
8
1
1
MECH 8CLIN 1GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Decreased H3K9ac at autophagy gene promoters in AD…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-18 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Novel Therapeutic Hypotheses: Comparative Epigenetic Signatures in Neurodegeneration
Hypothesis 1: HDAC6 Inhibitor Therapy for Pan-Neurodegenerative Protein Homeostasis Restoration
Description: Shared H3K9 deacetylation at promoters of autophagy genes (e.g., BECN1, SQSTM1/p62) across AD, PD, and ALS leads to impaired protein clearance and aggregation. HDAC6 inhibition would restore H3K9ac levels, upregulate autophagic flux, and reduce pathological protein aggregates characteristic of each disease (Aβ/tau in AD, α-synuclein in PD, TDP-43 in ALS).
Target: HDAC6
**Supporting ev
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Epigenetic Therapeutic Hypotheses in Neurodegeneration
Hypothesis 1: HDAC6 Inhibitor Therapy
Specific Weaknesses
Evidence-base conflates pan-HDAC and selective HDAC6 inhibition: The cited PMID:28161408 references pan-HDAC inhibition in ALS models, not HDAC6-selective inhibition. HDAC6 is primarily cytoplasmic (deacetylates α-tubulin, Hsp90) and has distinct functions from nuclear HDAC1/2/3 targeted by many "HDAC inhibitors." Tubastatin A and other HDAC6-selective compounds show limited CNS penetration in most studies.
**Autophagy modulation is co
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Drug Development Reality Assessment: Epigenetic Targets in Neurodegeneration
Executive Summary
The seven hypotheses span mechanistically diverse epigenetic targets, but all face a common triad of challenges: blood-brain barrier (BBB) penetration, narrow therapeutic indices, and inadequate human translation data. Below I provide target-by-target practical realities, followed by cross-cutting recommendations.
Hypothesis 1: HDAC6 Inhibitor Therapy
Is the Target Druggable? What's the Chemical Matter?
Yes, HDAC6 is druggable, but with caveats. HDAC6 is a cy
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF 5xFAD mice (Alzheimer's model) receive chronic HDAC6 inhibitor (tubastatin A, 10mg/kg/day) via osmotic pump for 8 weeks starting at 3 months of age, THEN soluble aggregated tau levels in cortical tissue will decrease by ≥30% compared to vehicle-treated controls, as measured by biochemical fractionation and ELISA.
pendingconf: 0.45
Expected outcome: ≥30% reduction in soluble hyperphosphorylated tau aggregates in cortical brain regions
Falsified by: No significant difference (p>0.05) in tau aggregation between HDAC6 inhibitor and vehicle groups after 8 weeks of treatment, or increase in tau pathology
Method: 5xFAD transgenic mice (n≥20 per group), biochemical fractionation, p-tau ELISA (AT270, INNOTEST), stereology for insoluble tau burden
IF early-stage Parkinson's disease patients receive HDAC6 inhibitor (ACY-738 or equivalent) at 50mg twice daily for 24 weeks, THEN CSF α-synuclein aggregate clearance rate will increase by ≥25% compared to baseline, as measured by seed amplification assay (RT-QuIC), with concurrent reduction in neurofilament light chain (NfL) trajectory.
pendingconf: 0.35
Expected outcome: ≥25% increase in α-synuclein clearance rate; stabilization or reduction of CSF NfL levels
Falsified by: CSF α-synuclein aggregate signal increases or remains unchanged; NfL levels rise by >15% indicating neuronal injury progression